MSC Neural Reprogramming Using Exosomes Without Transgenes

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for reprogramming mesenchymal stem cells (MSCs) into neural progenitor cells are risky, invasive, and costly, and they do not naturally originate from the ectodermal germ layer, making their use for neurological diseases challenging.

Innovation Solution

A method using 5-aza-2′-deoxycytidine and exosomes derived from neural stem cells to epigenetically reprogram MSCs into neural progenitors without transgenes, in a xeno-free and time-efficient manner, utilizing a scaffold-free culture medium.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional reprogramming methods are used to convert MSCs into neural progenitor cells, then neural cell production is achieved, but the process becomes risky, invasive, and costly

Engineering Contradiction:

Improvesafety of reprogrammingVSAvoidcomplexity of reprogramming process

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent extracts and eliminates transgenes and xeno components from the reprogramming process. By using only human-derived components (human neural stem cell exosomes and human MSCs) and removing the need for genetic modification, the method achieves safer reprogramming that is less invasive and more suitable for clinical applications

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent introduces exosomes derived from human neural stem cells as an intermediary substance to mediate the reprogramming of MSCs. These exosomes carry bioactive molecules that induce neural differentiation without requiring direct genetic manipulation, thereby reducing risk and invasiveness while maintaining effectiveness

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If conventional reprogramming approaches are applied, then neural progenitors can be produced, but the process is time-consuming and costly

Engineering Contradiction:

Improveproduction efficiency of neural progenitorsVSAvoidreprogramming duration

Core Design Contradiction:

ProductivityVSLoss of time

Solution Approach 1:

The patent employs preliminary action by pre-differentiating neural stem cells into exosome-secreting cells before using their exosomes for MSC reprogramming. This preparatory step creates a ready supply of bioactive exosomes that can rapidly induce neural differentiation, reducing overall reprogramming time and improving production efficiency

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses exosomes as a copy or surrogate of direct neural stem cell contact. Instead of requiring direct interaction with neural stem cells or complex genetic engineering, the exosomes copy and transmit the essential differentiation signals, achieving faster and more cost-effective reprogramming

Inventive Principle:

Principle #26Copying

3Adaptability or versatility

If MSCs are used for neurological diseases, then accessibility and abundance are improved, but the challenge remains that they do not naturally originate neural cells

Engineering Contradiction:

Improvesuitability for neurological applicationsVSAvoidbiological authenticity of neural differentiation

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent changes the biological parameters of MSCs through epigenetic modification induced by exosomal components. By altering gene expression patterns without changing the underlying DNA sequence, the method transforms MSCs into neural progenitors with authentic neural characteristics, maintaining biological reliability while achieving versatility for neurological applications

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent converts the inherent limitation of MSCs (their mesodermal origin incompatible with neural lineage) into an opportunity. By using exosomes to induce transdifferentiation through epigenetic reprogramming, the method overcomes the germ layer barrier and enables MSCs to reliably generate authentic neural cells, making them suitable for neurological disease treatment

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enables cost-effective and rapid production of neural progenitors, suitable for clinical applications, including autologous therapies, by bypassing pluripotent stages and avoiding animal products.

Implementation Method 1

treating the mesenchymal stem cells with an epigenetic modifier that modifies epigenetic marks on the mesenchymal stem cells

Methodology Applied

Scientific EffectEpigenetic modification:

Implementation Method 2

providing the treated mesenchymal stem cells with exosomes derived from neural stem cells as a source of lineage specific signals

Methodology Applied

Scientific EffectExosome-mediated signaling:

Data Source

PatentUS12577532B2Xeno-free and transgene-free reprograming of mesenchymal stem cells toward neural progenitor cells

Publication Date: 2026.03.17 UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION INC

AI summary

Disclosed herein are methods and materials for transdifferentiating mesenchymal stem cells into neural progenitor cells.